Ralph Joseph, MD
Family Medicine · Little Rock, ARNPI 1881686962
Payments from drug & device makers
Across 350 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$571
- Abbott$571
- Pfizer$513
- Amgen$389
- Novo Nordisk$372
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,46798%
- Education$1322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,031 |
| AstraZeneca | 22 | $571 |
| Abbott | 29 | $571 |
| Pfizer | 31 | $513 |
| Amgen | 22 | $389 |
| Novo Nordisk | 38 | $372 |
| Lilly USA, LLC | 19 | $290 |
| Amarin Pharma, Inc. | 11 | $197 |
| Merck | 12 | $188 |
| Astellas Pharma US Inc | 5 | $181 |
| Novartis | 9 | $167 |
| Shield Therapeutics Inc | 6 | $100 |
| Exact Sciences | 6 | $91 |
| Esperion Therapeutics, Inc. | 6 | $89 |
| Boston Scientific | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| GSK | 5 | $77 |
| Boehringer Ingelheim | 4 | $76 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $32 |
| Bayer | 2 | $25 |
| Johnson & Johnson | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,598 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $45,494 |
| FarxigaDapagliflozin Propanediol | 42 | $40,821 |
| EliquisApixaban | 51 | $39,874 |
| TrulicityDulaglutide | 29 | $31,519 |
| MounjaroTirzepatide | 26 | $28,287 |
| JardianceEmpagliflozin | 37 | $26,683 |
| JanuviaSitagliptin Phosphate | 16 | $19,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,797 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $13,814 |
| MultaqDronedarone Hcl | 11 | $12,907 |
| EntrestoSacubitril/Valsartan | 14 | $12,412 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $8,896 |
| Atorvastatin Calcium | 717 | $6,442 |
| Metoprolol Succinate | 408 | $5,529 |
| Gabapentin | 168 | $4,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $290 | $59,80655 claims |
| Novo NordiskOzempic | $372 | $45,49448 claims |
| AstraZenecaFarxiga | $571 | $40,82142 claims |
| PfizerEliquis | $513 | $39,87451 claims |
| MerckJanuvia, Janumet Xr | $188 | $32,92632 claims |
| Boehringer IngelheimJardiance | $76 | $26,68337 claims |
| GSKTrelegy Ellipta | $77 | $16,79720 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $12,90711 claims |
| NovartisEntresto | $167 | $12,41214 claims |
| AbbVieSynthroid | $1,031 | $1,50828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Senthil RaghavanLittle Rock$496K
- Benny GreenLittle Rock$150K
- Lee NaylesLittle Rock$114K
- Steve SimpsonLittle Rock$34K
- Harold BettonLittle Rock$18K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.